Protara Therapeutics (TARA) investors approve share increase and pay items
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Protara Therapeutics, Inc. held its Annual Meeting of Stockholders, where all seven proposals received stockholder approval. Stockholders elected three Class III directors to serve until the 2029 annual meeting and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Stockholders approved, on an advisory basis, executive compensation and set the say‑on‑pay vote frequency at one year. They also approved an amendment to the 2024 Equity Incentive Plan and an amendment to increase authorized common shares from 100,000,000 to 200,000,000. An additional charter amendment allowing officer exculpation, as permitted by Delaware law, was also approved.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding record date: 55,060,500 shares
Authorized common shares after amendment: 200,000,000 shares
Auditor ratification votes for: 45,012,036 votes
+3 more
6 metrics
Shares outstanding record date
55,060,500 shares
Common stock outstanding and entitled to vote as of April 15, 2026
Authorized common shares after amendment
200,000,000 shares
Authorized common stock increased from 100,000,000 via charter amendment
Auditor ratification votes for
45,012,036 votes
Votes for ratifying Ernst & Young LLP for year ending December 31, 2026
Say-on-pay approval votes for
29,208,205 votes
Advisory approval of named executive officer compensation
Equity plan amendment votes for
18,094,953 votes
Approval of amendment to 2024 Equity Incentive Plan
Officer exculpation votes for
29,642,641 votes
Approval of charter amendment allowing officer exculpation under Delaware law
Key Terms
broker non-votes, say-on-pay, 2024 Equity Incentive Plan, authorized shares of common stock, +1 more
5 terms
broker non-votes financial
"Votes For | | Votes Against | | Abstentions | | Broker Non-Votes 29,208,205 | | 1,656,994 | | 48,666 | | 14,185,811"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
say-on-pay financial
"Vote, on an Advisory Basis, on the Frequency of the Say-On-Pay vote."
A say-on-pay is a shareholder vote that gives investors a chance to approve or disapprove a company’s executive compensation packages, typically held at annual meetings. It matters because the vote signals investor satisfaction with how leaders are paid—like customers rating how well managers are rewarded—and can push boards to change pay plans, reducing governance risk and affecting investor confidence and stock value even though the vote is usually advisory rather than legally binding.
2024 Equity Incentive Plan financial
"Approval of an Amendment to the Protara Therapeutics, Inc. 2024 Equity Incentive Plan."
officer exculpation regulatory
"Allowing Officer Exculpation as Permitted by Delaware Law."
A charter clause that limits company officers’ personal responsibility for money damages when they make business decisions that turn out poorly, unless they acted in bad faith, engaged in intentional wrongdoing, or took improper personal gain. It matters to investors because it changes the practical risk and accountability for senior managers—similar to giving a driver limited crash liability, it can encourage bold decision-making but may reduce the chance shareholders can recover losses if officers behaved improperly.
FAQ
What did Protara Therapeutics (TARA) stockholders approve at the 2026 annual meeting?
Stockholders approved all seven proposals, including director elections, auditor ratification, advisory say-on-pay, annual say-on-pay frequency, an amendment to the 2024 Equity Incentive Plan, doubling authorized common shares to 200,000,000, and a charter amendment allowing officer exculpation under Delaware law.
How did Protara Therapeutics (TARA) stockholders vote on the director elections?
Stockholders elected three Class III directors. Jesse Shefferman received 26,672,259 votes for, Barry Flannelly received 25,409,066, and Cynthia Smith received 22,371,125, each with broker non-votes of 14,185,811, to serve until the 2029 annual meeting and until successors are qualified.
What were the say-on-pay results for Protara Therapeutics (TARA) in 2026?
Stockholders approved, on an advisory basis, named executive officer compensation, with 29,208,205 votes for, 1,656,994 against, and 48,666 abstentions. They also supported holding the advisory say-on-pay vote every one year, with 26,766,824 votes favoring the annual frequency option.
Which auditor did Protara Therapeutics (TARA) stockholders ratify for 2026?
Stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, casting 45,012,036 votes for, 74,615 votes against, and 13,025 abstentions, indicating broad support for the audit firm’s continued engagement.